Assenagon Asset Management S.A. Acquires 151,021 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Assenagon Asset Management S.A. raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 54.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 428,949 shares of the company's stock after acquiring an additional 151,021 shares during the period. Assenagon Asset Management S.A. owned approximately 0.50% of Syndax Pharmaceuticals worth $8,806,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SNDX. Arizona State Retirement System raised its stake in Syndax Pharmaceuticals by 5.3% during the 4th quarter. Arizona State Retirement System now owns 16,511 shares of the company's stock valued at $357,000 after acquiring an additional 835 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Syndax Pharmaceuticals by 11.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,897 shares of the company's stock valued at $1,013,000 after acquiring an additional 4,705 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Syndax Pharmaceuticals by 9.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company's stock valued at $305,000 after acquiring an additional 1,162 shares in the last quarter. Signaturefd LLC raised its stake in Syndax Pharmaceuticals by 2,874.6% during the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company's stock valued at $81,000 after acquiring an additional 3,622 shares in the last quarter. Finally, CWM LLC raised its stake in Syndax Pharmaceuticals by 415.3% during the 4th quarter. CWM LLC now owns 1,685 shares of the company's stock valued at $36,000 after acquiring an additional 1,358 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Jefferies Financial Group assumed coverage on Syndax Pharmaceuticals in a research note on Friday, June 28th. They set a "buy" rating and a $37.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. HC Wainwright lifted their price target on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday. Scotiabank cut Syndax Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, June 14th. Finally, Barclays lifted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.33.

Insider Activity

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan purchased 1,250 shares of the stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $20.03 per share, for a total transaction of $25,037.50. Following the completion of the acquisition, the chief financial officer now owns 52,623 shares of the company's stock, valued at approximately $1,054,038.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is currently owned by corporate insiders.

Syndax Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ SNDX traded down $0.03 during mid-day trading on Friday, reaching $19.93. The company had a trading volume of 632,845 shares, compared to its average volume of 1,045,821. The stock has a market cap of $1.70 billion, a PE ratio of -6.19 and a beta of 0.94. The company has a 50-day moving average price of $21.22 and a two-hundred day moving average price of $21.69. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. During the same quarter last year, the company earned ($0.64) EPS. The company's quarterly revenue was up 3499999990.0% compared to the same quarter last year. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.64 EPS for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).